Polyspecific Antibodies in Lymphoproliferative T-cell Disorders
NCT06495723
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
54
Enrollment
INDUSTRY
Sponsor class
Conditions
Peripheral T Cells Lymphoma (PTCL)
Interventions
DRUG:
LIS1
Sponsor
Xenothera SAS